ConforMIS Stock News

Equities analysts expect Conformis, Inc. (NASDAQ:CFMS) to announce earnings of ($0.07) per share for the current quarter, Zacks reports. Two analysts have provided estimates for Conformis earnings. The highest EPS estimate is ($0.06) and the lowest is ($0.08). Conformis posted earnings of ($0.08) per share in the same quarter last year, which indicates a positive []

Wall Street analysts forecast that Conformis, Inc. (NASDAQ:CFMS) will report earnings of ($0.07) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Conformis earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.08). Conformis posted earnings per share of ($0.08) []

Conformis, Inc. (CFMS) with the stream of -7.62% also noticed, India KAR Auction Services, Inc. (KAR) encountered a rapid change of 6.13% in the last hour of trading session. Conformis, The post Lumpy Stock: Conformis, Inc. (NASDAQ:CFMS), KAR Auction Services, Inc. (NYSE:KAR) appeared first on Stocks Equity .

Conformis, Inc. (CFMS) with the stream of -7.62% also noticed, India Pulmatrix, Inc. (PULM) encountered a rapid change of -1.53% in the last hour of Fridays trading session. Conformis, Inc. The post Sizzler Stock is not to be missed: Conformis, Inc. (NASDAQ:CFMS), Pulmatrix, Inc. (NASDAQ:PULM) appeared first on Stocks Equity .

Cubist Systematic Strategies LLC bought a new stake in Conformis, Inc. (NASDAQ:CFMS) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 83,002 shares of the medical instruments suppliers stock, valued at approximately $95,000. Several other hedge funds have also recently []

TheStreet cut shares of Conformis (NASDAQ:CFMS) from a c rating to a d+ rating in a research report report published on Friday morning, TheStreetRatingsTable reports. CFMS has been the topic of a number of other reports. Oppenheimer dropped their price target on shares of Conformis from $2.50 to $2.00 and set an outperform rating on []

TheStreet lowered shares of Conformis (NASDAQ:CFMS) from a c rating to a d+ rating in a report published on Friday, TheStreetRatingsTable reports. Several other analysts have also commented on the stock. Zacks Investment Research raised shares of Conformis from a sell rating to a hold rating in a research report on Tuesday, November 16th. Oppenheimer []

Prominent joint reconstruction devices manufacturers across the globe include Stryker, ConforMIS, Smith & Nephew, NuVasive, Medtronic, Globus Medical, Medacta, Zimmer Biomet, DJO Global, MicroPort Scientific Corporation, and Waldemar LINK. Prominent joint reconstruction devices manufacturers across the globe include Stryker, ConforMIS, Smith & Nephew, NuVasive, Medtronic, Globus Medical, Medacta, Zimmer Biomet, DJO Global, MicroPort Scientific Corporation, and Waldemar LINK.

Conformis, Inc. (CFMS) with the stream of -5.27% also noticed, India Globalstar, Inc. (GSAT) encountered a rapid change of -1.40% in the last hour of Mondays trading session. Conformis, Inc. The post Top-notch Stock: Conformis, Inc. (NASDAQ:CFMS), Globalstar, Inc. (AMEX:GSAT) appeared first on Stocks Equity .

Wall Street analysts forecast that Conformis, Inc. (NASDAQ:CFMS) will announce sales of $16.04 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Conformis earnings. The lowest sales estimate is $15.97 million and the highest is $16.11 million. Conformis posted sales of $16.70 million in the same quarter []

Conformis Inc. (NASDAQ:CFMS) shares, rose in value on Friday, 11/26/21, with the stock price down by -4.81% to the previous days close as strong demand from buyers drove the stock to $0.93. Actively observing the price movement in the last trading, the stock closed the session at $0.98, falling within a range of $0.91 and Conformis Inc. (NASDAQ: CFMS) Stock Seems Like A Good Option Read More »

Key Players covered in the Knee Replacement Market Research Report are Zimmer Biomet (Indiana, U.S.), Stryker (Michigan, U.S.), DePuySynthes Companies (Johnson & Johnson Services, Inc.) (Indiana, U.S.), Smith & Nephew (London, U.K.), Aesculap, Inc. a B. Braun company (Center Vally, USA), Medacta International (Castel San Pietro, Switzerland), MicroPort Scientific Corporation (Shanghai, China), Conformis (Massachusetts, U.S.), Other Prominent Players. Key Players covered in the Knee Replacement Market Research Report are Zimmer Biomet (Indiana, U.S.), Stryker (Michigan, U.S.), DePuySynthes Companies (Johnson & Johnson Services, Inc.) (Indiana, U.S.), Smith & Nephew (London, U.K.), Aesculap, Inc. a B. Braun company (Center Vally, USA), Medacta International (Castel San Pietro, Switzerland), MicroPort Scientific Corporation (Shanghai, China), Conformis (Massachusetts, U.S.), Other Prominent Players.

Zacks Investment Research upgraded shares of Conformis (NASDAQ:CFMS) from a sell rating to a hold rating in a report published on Tuesday morning, Zacks.com reports. According to Zacks, ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Companys iFit technology platform consists of iFit Design, iFit Printing and []

Conformis Inc. (NASDAQ:CFMS) price on Thursday, November 18, fall -2.76% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.95. A look at the stock’s price movement, the level at last check in today’s session was $0.97, moving within a range at $0.961 and $1.04. The beta value … Conformis Inc. (CFMS): At $0.95, It’s Worth Your Attention Read More »